Some of the biggest blockbusters known to the pharma industry have dropped off the patent cliff and tumbled into the brutal land of generic therapies, where low-priced competition lays sales to waste. The once-mighty Lipitor is finished as a big earner, as we see in our new list of the 15 top-selling pharmaceuticals in 2012. In place of the small molecule standbys, biologics like Humira have risen to the top.

See on www.fiercepharma.com